Loading
Thousands of cancer biomarkers are published; almost none reach patients because nobody validates them fairly. Create a public service that tests any candidate blind against stored samples.
Biomarker failure stems from small discovery sets, spectrum bias and absence of blinded validation on prospectively collected samples. Cohorts with pre-diagnostic samples (UK Biobank, PLCO, national screening biobanks) and trial biorepositories exist but access is slow and fragmented. The proposal is a funded utility: a governed catalogue of pre-diagnostic and trial samples with outcomes, a standard blinded validation protocol (PRoBE design), rapid access for academic and commercial developers at cost, and public reporting of all results including failures.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Preclinical results do not reproduce, Biomarkers are not validated or standardised.
Shares Proteomics & phosphoproteomics, Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Biomarkers are not validated or standardised, Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Preclinical results do not reproduce.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Biomarkers are not validated or standardised.
Shares Proteomics & phosphoproteomics, Liquid biopsy (ctDNA).
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Biomarkers are not validated or standardised.